[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643962":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":51,"collaborators":11,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":11,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":67,"briefSummary":70,"conditions":71,"keywords":11,"overallStatus":73,"whyStopped":11,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral Prednisone Group","ACTIVE_COMPARATOR",null,[13],"Drug: Prednisone",{"label":15,"type":16,"description":11,"interventionNames":17},"Intramuscular Compound Betamethasone Group","EXPERIMENTAL",[18],"Drug: Compound betamethasone",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Prednisone","Prednisone, oral administration. Starting dose of 40 mg once daily for 2 weeks, followed by gradual tapering according to the following schedule: reduce by half a tablet (2.5 mg) each week. When the dose is reduced to 1 tablet (5 mg) once daily, maintain for 2 weeks; then reduce to half a tablet (2.5 mg) once daily for 2 weeks; then reduce to half a tablet (2.5 mg) every other day for 2 weeks; then reduce to half a tablet (2.5 mg) twice weekly for 2 weeks, then discontinue. Total treatment duration is 24 weeks.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Compound betamethasone","Compound Betamethasone injection, administered intramuscularly. Each injection is 1 mL, given once every 4 weeks for a total of 6 injections, with a treatment period of 24 weeks.",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Hui Huang","CONTACT","86+13391587917","pumchhh@126.com",[36],{"facility":37,"status":11,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","Beijing","Beijing Municipality","100730","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},{"type":52,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100643962","phase-2-evaluation-of-the-efficacy-and-safety-of-compound-betamethasone-in-pulmonary-sarcoidosis-100643962",false,"NCT07668895","Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis","A Prospective, Multi-center, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Diagnosed within the past 3 months with stage I-II (based on chest CT) treatment-naive pulmonary sarcoidosis, meeting the following: A. Histopathological diagnosis of sarcoidosis via tissue biopsy (bronchial mucosa, intrathoracic lymph nodes, lung, pleura, etc.) obtained during bronchoscopy; B. Chest HRCT showing mediastinal and hilar lymphadenopathy, with or without pulmonary infiltrates (nodules, patchy opacities, ground-glass opacities, etc.); C. CT stage confirmed independently by at least two experts in the field (among three experts reviewing the chest HRCT images).\n* Requiring systemic glucocorticoid therapy.\n* Able to complete scheduled follow-up visits.\n* Patient and family members understand the study protocol, are willing to participate in this study, and are able to provide written informed consent.\n\nExclusion Criteria:\n\n* Patient or family members are unable to understand the conditions and objectives of this study, or are unable to provide informed consent.\n* Subjects who cannot comply with the follow-up schedule as required by the protocol.\n* Presence of other serious diseases that, in the investigator's judgment, may affect patient safety or compliance.\n* Any significant clinical or laboratory abnormalities that, in the investigator's judgment, may affect safety evaluation.\n* Pregnant or breastfeeding women, or patients who cannot use effective contraception during the study period and within 3 months after the study ends.\n* Active malignancy requiring treatment (surgery, medical therapy, or radiotherapy).\n* Hypersensitivity to Diprospan (Compound Betamethasone) or prednisone.","ALL","18 Years","100 Years",{"count":64,"type":65},126,"ESTIMATED","INTERVENTIONAL",[68,69],"PHASE2","PHASE3","The goal of this clinical trial is to learn whether a study drug called Compound Betamethasone (also known as Diprospan) works to treat pulmonary sarcoidosis in people with early-stage disease (stage I or II). It will also learn about its safety compared to the standard treatment, prednisone.\n\nThe main questions it aims to answer are:\n\n* How much does the study drug improve lung function (measured by a test called FVC%) after 24 weeks of treatment?\n* How does it compare to prednisone in controlling symptoms, reducing chest lymph node swelling, and preventing relapse? Researchers will compare Compound Betamethasone injections (given once every 4 weeks) to prednisone pills (taken daily with a gradual dose reduction).\n\nParticipants will:\n\n* Receive either the study drug injection or prednisone pills for 24 weeks\n* Visit the clinic for checkups and lung function tests at weeks 6, 12, and 24\n* Have chest CT scans and blood tests to monitor their condition and any side effects\n* Be followed up for additional 24 weeks (up to week 48) to see if the disease comes back after treatment stops",[72],"Sarcoidosis, Pulmonary","NOT_YET_RECRUITING","2026-06-21",{"date":76,"type":77},"2026-06-25","ACTUAL",{"date":79,"type":65},"2026-07",{"date":81,"type":65},"2028-07",{"name":5,"class":6},1]